Participated · Series C · Jun 2021

Hospital IQ offers a cloud-based operations management platform that combines advanced data analytics, machine learning and simulation technology with an intuitive user interface to optimize surgical resource alignment, patient flow, and staff scheduling. Its AI-enabled platform integrates predictive analytics, workflows and communications to drive measurable operational improvements for hospitals and health systems. The company says hundreds of hospitals and health systems rely on its software and that it has become an industry standard in capacity operations management and optimization. Hospital IQ reported a record year in which revenue more than doubled, its customer base grew by 50%, and platform utilization increased 14x. The company plans to use new funding to accelerate product development, sales and marketing, client services, and to expand partnerships including Allscripts and Cerner. Hospital IQ also intends to hire aggressively, targeting 50% headcount growth by year-end and 100% growth within the next 12 months. PatientRoute Systems builds a predictive analytics platform used by hospitals and surgical centers to detect operational patterns and help reduce readmissions, shorten length of stay, improve on-time surgery starts, and reduce turnover time. The platform is aimed at analysts and department heads and is designed to support hospital clinical policy. The company currently serves clients across six states and focuses on hospitals and surgical centers with more than 400 beds. Customers include Greater Baltimore Medical Center and Boston Medical Center. PatientRoute was founded by CEO Rich Krueger in 2013 and is based in Boston. It raised $7 million to expand its platform and plans to use the capital to double its 12-person team, ideally by the end of the year.

Led · Equity · Jul 2015

NantBioScience, a wholly-owned subsidiary of NantWorks, focuses on creating targeted oncology drugs that match treatments to the molecular profile of each patient’s tumor rather than its anatomical origin. Leveraging next-generation sequencing, targeted proteomics, and large-scale supercomputing, the firm aims to replace traditional ‘trial-and-error’ clinical trial design with data-driven predictability. Its lead assets include two nab® product candidates—NTB-011, a colchicine-dimer with vascular-disrupting properties, and NTB-010, a geldanomycin-based HSP90 inhibitor—both cleared for IND and slated for Phase I trials in 2014-2015. Beyond nab® molecules, the pipeline features a KRAS inhibitor, p53-remediation compounds, and a library of over 4,000 multi-kinase inhibitors, several of which are expected to enter IND-enabling studies between 2014 and 2016. Founder Dr. Patrick Soon-Shiong reports that more than $100 million has already been invested internally to build this platform. The company’s mission is to deliver “right drug, right time” precision oncology therapies while minimizing side effects through molecularly guided patient selection.